Unknown

Dataset Information

0

CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia.

ABSTRACT:

SUBMITTER: Wintering A 

PROVIDER: S-EPMC9840233 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia.

Wintering Astrid A   Ishiyama Kenichi K   Tamaki Stanley S   Tamaki Courtney C   Fandel Joshua J   Ji Lingyun L   Wood Brent L BL   Shah Nirali N NN   Yuan Constance M CM   O'Brien Maureen M MM   Loh Mignon L ML   Diaz-Flores Ernesto E  

Blood advances 20230101 2

Similar Datasets

Unknown Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
| S-EPMC6438769 | biostudies-literature
Unknown Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
| S-EPMC6238377 | biostudies-literature
Unknown Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
| S-EPMC7414105 | biostudies-literature
Unknown Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.
| S-EPMC5908210 | biostudies-literature
Unknown Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
| S-EPMC6822860 | biostudies-literature
Unknown Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
| S-EPMC7983935 | biostudies-literature
Unknown Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
| S-EPMC6529376 | biostudies-literature
Unknown Real world outcomes with the use of Inotuzumab Ozogamicin in relapsed/refractory B cell acute lymphoblastic leukemia.
| S-EPMC12756246 | biostudies-literature
Unknown A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
| S-EPMC7995290 | biostudies-literature
Unknown Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
| S-EPMC6063246 | biostudies-literature